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A B S T R A C T
Qualitative studies show that patients suffering from Multiple Chemical Sensitivity (MCS) or Idiopathic 
Environmental Intolerance (IEI) are aware of health-care professionals’ non-awareness of the disease, 
making communication difficult. The objective of this paper is to describe the suffering in individuals with 
MCS and to assess the disease’s impact on each measured dimension of suffering by means of a descriptive 
and correlational study. A sample of 125 subjects fill out a survey consisting of three scales for assessing 
the impact of MCS and three scales for assessing suffering. The results show that MCS affects mostly 
women. Assessment with the Quick Environmental Exposure and Sensitivity Inventory (QEESI) showed 
that participants have high levels of disease. The physical sphere of suffering is the most affected, followed 
by the psychological and the existential. There are high correlations between the QEESI and suffering 
scales. A multivariate regression equation explained 38.2% of the variance of suffering observed. We 
conclude that MCS generates physical, psychological, and existential suffering. Severity of symptoms is the 
variable that generates most suffering, followed by life impact. Psychological distress is marked by anxiety 
or worry and lack of gaiety; existential suffering reveals thoughts of failure and lack of inner harmony. A 
detailed description of suffering in MCS is a useful basis for therapy. Lack of awareness among health-care 
personnel implies inattention of these patients within the general health-care service. With this 
investigation we hope to raise awareness of this emerging disease in order to improve the communication 
between health-care workers and patients.
© 2014 Colegio Oficial de Psicólogos de Madrid Production by Elsevier España, S.L. All rights reserved.
Evaluación del sufrimiento en personas que tienen sensibilidad química multiple
R E S U M E N
Los estudios cualitativos muestran que las personas que padecen sensibilidad química múltiple (SQM), o 
intolerancia ambiental idiopática, piensan que existe una falta de conciencia por parte de los profesionales 
sanitarios acerca de la enfermedad, lo que dificulta la comunicación. El objetivo de este trabajo es describir 
el sufrimiento de las personas que padecen SQM y evaluar la repercusión de la enfermedad en cada dimen-
sión del sufrimiento, mediante un estudio descriptivo y correlacional. Una muestra compuesta por 125 per-
sonas cumplimentaron una encuesta de tres escalas que miden el impacto de la SQM y tres escalas que 
miden el sufrimiento. Los resultados revelan que la SQM afecta sobre todo a mujeres. La evaluación me-
diante el Inventario Rápido de Exposición y Sensibilidad al Entorno (QEESI) mostró que los participantes 
padecían la enfermedad en grado elevado. La esfera física del sufrimiento es la más afectada, seguida de la 
psicológica y la existencial. La correlación entre el QUEESI y las escalas de sufrimiento es elevada. La ecua-
ción de regresión multivariada explicaba el 38.2% de la varianza del sufrimiento observada. Se concluye que 
la SQM produce sufrimiento físico, psicológico y existencial. La gravedad de los síntomas es las variable que 
más sufrimiento produce, seguido de la repercusión vital. El sufrimiento psicológico se caracteriza por la 
ansiedad o la preocupación y la falta de alegría. El sufrimiento existencial revela pensamientos de fracaso y 
falta de armonía interior. La detallada descripción del sufrimiento en la SQM constituye una base útil para 
la terapia. La carencia de conocimiento entre los profesionales sanitarios provoca falta de atención a estos 
pacientes por parte de los profesionales sanitarios. Esperamos con esta investigación inducir la toma de 
conciencia sobre esta enfermedad emergente para así poder mejorar la comunicación entre el personal sa-
nitario y los pacientes.
© 2014 Colegio Oficial de Psicologos de Madrid. Producido por Elsevier España, S.L. Todos los derechos reservados.
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Multiple Chemical Sensitivity (MCS), also termed Idiopathic 
Environment Intolerance (IEI) is a term used to describe a set of 
physical, cognitive, and emotional symptoms that appear when a 
person is exposed to low levels of a large variety of environmental 
chemicals including perfumes, household cleaning products, and 
paints which, prior to the onset of the disease, were well tolerated. 
In Spain the estimated prevalence is between 0.2% and 4% (Arnold et 
al., 2011).
Randolph (1954) highlighted that exposure to certain environmental 
chemicals could be the cause of a syndrome characterized by a variety 
of symptoms which, in current terms, would correspond to MCS. Later, 
Cullen (1987) described the syndrome as an “acquired disorder 
characterized by recurrent symptoms referable to multiple systems, 
occurring in response to many chemical unrelated compounds at 
doses far below those established as causing harmful effects in the 
general population”. This definition has been subjected to many 
objections and suggestions that attempted to refine and/or broadened 
it (Labarge & McCaffrey, 2000). Thus, a group of 89 clinicians and 
researchers with different views of the etiology of the disease 
established 5 diagnostic criteria to define MCS (Nethercott , Davidoff, 
Curbow, & Abbey, 1993). These were: 1) the condition must be chronic; 
2) the symptoms should be reproducible; 3) the response should 
occur at low exposure levels; 4) the response needs to be to multiple 
chemical substances; and 5) the response is improved when the 
trigger substance is removed. Bartha et al. (1999) included a 6th 
criterion, i.e., the symptomatology should involve multiple organ 
systems. These 6 criteria (5 +1) are known as the Consensus Criteria. 
The range of physical symptoms associated with MCS is very 
broad and related to multiple systems. In a systematic review 
conducted by Labarge & McCaffrey (2000) 151 symptoms were 
identified that were especially related to the central nervous system 
(CNS) and respiratory and gastrointestinal tracts. Subsequent studies 
(Lacour, Zunder, Schmidtke, Vaith, & Scheidt , 2005) highlighted the 
prevalence of non-specific symptoms related with the CNS such as 
headache, fatigue, and cognitive deficits. More recently, Nogué et al. 
(2007) in a study involving 52 cases found that the predominant 
symptoms were irritation of the oropharyngeal mucosa and 
breathing problems. In the same study, they found that people were 
mostly intolerant to chemical products found in household cleaning 
items, as well as perfumes and toiletries. Gibson and Vogel (2009) 
established that most of the symptoms were caused by pesticides, 
formaldehyde, fresh paint, new carpets, gasoline fumes, fragrances, 
and air fresheners. A further 29 chemicals that were associated with 
symptoms in the study participants were also listed.
The etiology of MCS is difficult to define since there is no accepted 
physiopathological mechanism that may explain the clinical 
symptoms. Hence, the diagnosis of the disease is clinical and is based 
on the patient’s history and clinical examination. Currently, there is 
the support of an assessment tool called the Quick Environmental 
Exposure and Sensitivity Inventory (QEESI) which is composed of 5 
scales that can help assess the extent of the disease and the chemical 
triggers (Miller & Prihoda, 1999).
The dearth of physiological markers and diagnostic tests that 
would facilitate a definitive diagnosis has led to the development of 
several treatment options, many of them may not have been 
scientifically validated and, hence, the controversy surrounding MCS 
continues (Fox, Joffres, Sampalli, & Cas, 2007; Ortega, 2005). 
Individuals with MCS increasingly resort to alternative treatments 
and innovative strategies to manage their symptoms. Of considerable 
note is that the information obtained in informal interviews with the 
patients indicates that these alternative therapies are valued more 
highly than those provided by the official state-sponsored National 
Health System (NHS) and are perceived as being more useful (Koch, 
Vierstra, & Penix , 2006). 
Most studies have focused on evaluating, via qualitative 
methodology, the impact of MCS on the quality-of-life (QoL) of the 
individuals involved. Some studies (Gibson, Sledd, McEnroe, & Vos, 
2011; Koch, 2006; Skovbjerg, Brorson, Rasmussen, Johansen, & 
Elberling, 2009) describe the impact of MCS on daily-life activities, as 
well as the psychological and social effects of daily living while 
trying to avoid certain chemicals. 
As highlighted by patients, routine tasks such as shopping or 
using public transport can represent an exposure that will induce the 
symptoms. With respect to social restrictions, the patients emphasize 
the need for other people to understand their problem, which 
otherwise could lead to breakdown in relationships and 
stigmatization; the result could be a lack of openness regarding the 
condition. Working conditions require adjustments and colleagues’ 
collaboration, and these are not always possible. Of critical 
importance is that the medical profession is ignorant of the disease 
or has a low priority for clinical attention. 
Nordin, Andersson, and Nordin (2010) described the most 
commonly used coping strategies of people with MCS. Most strategies 
focused directly on the problem such as avoiding odorous 
environments and also requesting that their most intimate colleagues 
avoid the use of the symptom-inducing perfumes and/or deodorants. 
However, a resigned acceptance of the situation appears to be most-
often chosen. High levels of MCS are associated with the use of 
problem-focused strategies and mild degrees of disease with 
emotion-focused strategies. Although this co-occurrence of 
symptoms and experiences in the person with MCS could contribute 
to the suffering experienced at some point in the process, we have 
not encountered any published study evaluating the experience of 
suffering in this patient population. 
Cassell (1982) conceived suffering as a “state of severe distress 
specifically related to the imminent threats, perceived or actual, to 
the integrity or existential continuity of the person”. Later, Chapman 
and Gravin (1993) broaden Cassell’s definition to include suffering as 
“an affective and cognitive negative and complex state characterized 
by negative feelings experienced by a person who is threatened in 
their integrity, because of their sense of impotence to deal with this 
threat and exhaustion of personal and psychosocial resources that 
would deal with it”. 
Following-up on the definition of Chapman and Gravin (1993), 
Bayés, Arranz, Barbero, and Barreto (1997) proposed an intervention 
model known as the “Threat and Resources Model”. According to this 
model, a person suffers if: 1) something happens that he/she 
perceives as a threat or harm to his/her integrity, or to someone or 
something considered of vital importance to his/her integrity; and 2) 
the person assesses his/her resources as being insufficient to cope 
with the threat. 
Recently, Krikorian and Limonero (2012) widened the model 
proposed by Bayés. They considered that suffering occurs when the 
perception of threat involves damage to personal integrity, resources, 
and regulatory processes (including coping strategies and 
neurophysiological processes involved in the stress response) that 
are perceived as being insufficient, leading to psycho-social depletion 
and exhaustion. According to this holistic view, suffering is a global, 
multi-dimensional (physical, psychological, social, and spiritual), 
and dynamic experience. 
Assessment of suffering is essentially subjective. The causes of 
suffering, as well as their expression, are varied and dynamic in 
nature. Hence, the clinical interview appears to be the tool-of-choice, 
since the patient’s experiences are tested directly and individually. 
Currently, several instruments and tools that facilitate quantitative 
assessment of suffering have been developed. The one by Schulz et 
al. (2010) made a compilation and integration of previously-
developed instruments, extracting a set of items that do not overlap 
and which can be organized in 3 dimensions: physical symptoms, 
psychological distress, and spiritual or existential aspects. 
This construct may be more appropriate than the quality-of-life 
(QoL) concept used in previous studies because: 1) the QoL is 
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assessed with items that investigators consider as the basis of the 
problem but which often do not coincide with the patient’s 
perception of what constitutes a threat and causes suffering; 2) QoL 
dimensions need to be stable, which makes it difficult to approximate 
to the subjective experience of the sufferer which, by definition, is 
very changeable; and 3) a person’s existential dimension has little 
influence on QoL evaluation, but is a dimension that could be 
seriously affected by this disease. 
Hence, the main objectives of this study were: to describe 
suffering in individuals diagnosed with MCS; to identify the 
dimensions of suffering (using three questionnaires) that contribute 
the most to the MCS patient’s suffering; and to relate any differences 
in the measured variables to the severity of the disease.
Method
Design
A descriptive, correlational, cross-sectional, quantitative design 
was used.
Sample 
For the present study we carried out convenience sampling, i.e., 
extended participation to all those individuals who visited the blog 
“Mi Estrella de Mar” (http://mi-estrella-de-mar.blogspot.com/) 
between March 27th 2012 and April 12th 2012, and who met the 
criteria specified below. 
The blog “Mi Estrella de Mar” [My Sea Star] is a pioneer space for 
disseminating information on MCS. It has several quality accreditations, 
including the Physicians Association, WIS (Web of Health Interest), 
HON Code, Disability Information Service (Ministry of Health), M21, 
and Health Documentary. We chose this access path for sample 
selection because currently, there are no public health centers in 
Catalonia for the diagnosis and treatment of this disease.
Inclusion criteria: 
• Diagnosed as having MCS 
• Aged > 18 years
• Informed consent to participation in the study 
Exclusion criteria 
•  Pregnant (due to common transient intolerance to odors 
during pregnancy).
The final sample consisted of 125 persons, of whom 91.2% were 
women with a mean of 47 years of age and most (84%) living in urban 
areas. 
Instruments
Quick Environmental Exposure and Sensitivity Inventory (QEESI). 
This questionnaire was created by Claudia Miller and Thomas J. Prihoda 
in 1999 with the aim of providing the scientific community with a 
useful tool to assess individuals with MCS, which had not been so far 
described as an entity. The QEESI is a short version of the Environmental 
Exposure and Sensitivity Inventory (EESI). It is an instrument with 5 
subscales of 10 items each, with 11 Likert response options in 4 of the 
subscales and 4 options in 1 subscale. Its psychometric properties 
indicate an internal consistency of between .89 and .97 in the different 
subscales, together with a sensitivity of 92% and a specificity of 95% as 
a screening tool for the MCS. It is the questionnaire recommended by 
the Consensus of 1999 to assess MCS symptoms.
A Spanish version of this questionnaire is available and has been 
validated. Internal consistency reliability achieved Cronbach’s alphas 
of .94, .96, and .86 for symptom severity scales, chemical intolerances, 
and impact on QoL respectively.
The Spanish version was used in the current study. The α values 
obtained in the Severity Scales, Inhalatory Intolerances, and Life 
Impact were .864, .938, and .862 respectively.
Currently there are no screening cut-off points for the Spanish 
version of this questionnaire but the cut-off points recommended by 
the authors of the original version to detect disease are those that 
correspond to high scores ≥ 40 on Severity and Intolerances and ≥ 25 
on Life Impact. The cut-off points recommended to detect disease-
free individuals are those corresponding to low scores ≤ 20, 20, and 
10 respectively.
Scales of suffering. The suffering variable has been measured 
with ad hoc questionnaires made via modifications of the 
questionnaire proposed by Schulz et al. (2010), which assesses three 
dimensions of suffering: physical, psychological, and existential.
The physical suffering scale consists of 10 questions with Likert 
scores of 0 to 3, where 0 is nothing and 3 is a lot. The psychological 
suffering scale consists of 15 questions with the same options as 
the previous scale and, finally, existential suffering scale consists 
of 9 items with responses from 0 to 4, where 0 is nothing and 4 is 
much.
The evaluation of the psychometric characteristics of the original 
questionnaire achieved an acceptable reliability (internal consistency 
and test-retest) and validity (principal component analysis, 
convergent, and discriminant validity) in the three samples tested by 
the authors.
For this research we have made some changes in the physical 
scale, which has been adapted to the symptoms reported by 
individuals suffering MCS. Also, because of the lack of a Spanish 
version of the instrument we made a translation, which was back-
translated by another person not connected to the study. 
The Cronbach alpha obtained in this study for the full scale trial 
was .934 and for the physical, psychological, and existential 
dimensions the alpha values were .82, .92, and .89 respectively.
The format of both instruments, QEESI and suffering scales, have 
been adapted for electronic format and uploaded onto a web platform 
dedicated to survey management. The first question of the survey 
was a mandatory question and if the respondents were unable to 
answer, they were stopped from getting further. The question 
addressed informed consent, which explained the research’s title, 
the objectives of the study, guarantee of confidentiality, and the 
requirement for informed consent to participating. The survey was 
revised and approved by the blog’s author.
As control measures, we restricted access to the survey form to 
only one person/computer, and once a question had been answered 
progress was made to the next stage. Reversal was not permitted. 
Questionnaires are annexed.
Procedure 
Initially, we contacted the blog’s author (María José Moya Villén) 
to explain the objectives of the project and to request permission to 
invite participants into the research program via her blog. Once she 
agreed, she posted a link to the questionnaire on the blog home page 
“Mi Estrella de Mar” [My Sea Star]. The call for participation was 
posted across different groups in the social network, including 
Facebook, the websites of the “Asociación Alicantina para el Estudio 
de las Intolerancias Alimentarias y Ambientales” [Alicante Association 
for the Study of Intolerance in Food and Environment] (http://aaeiaa.
wordpress.com/), and “Todoalergias” [AllAllergies] (http://www.
todoalergias.com/). 
Diffusion was made via a pdf document, which provided 
information concerning the research (aim, questionnaires) and the 
principal investigator (profession, workplace). Individuals who 
agreed to participate were linked into the survey and the data sent 
automatically to the principal investigator. All data were codified to 
ensure anonymity. 
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Data Analysis 
Completed questionnaires were collected in an Excel 2007 
database and analyzed using SPSS (Statistical Package for Social 
Sciences version 17 for Windows). Descriptive statistics were used 
to describe the socio-demographic and clinical variables. The 
degree or extent of disease was evaluated by comparing means of 
independent samples using Student’s t-test. The Pearson correlation 
coefficient was used to check for associations between variables. 
Multiple linear regression analyses were applied to establish a 
predictive model of suffering. A value of p < .05 was considered 
statistically significant.
Results
Description of the Socio-demographic Characteristics of the 
Study Sample 
The characteristics of participants are summarized in Table 1. Of 
the 125 participants in the study, 114 were women and 11 were men, 
aged between 26 and 72 years with a mean age of 47. Most were 
urban dwellers, well educated (mainly university graduates), 
predominantly unemployed due to their MCS disability, and married 
or in a stable partnership. Concomitant diseases included 
fibromyalgia, chronic fatigue, and other chronic diseases such as 
hypothyroidism, irritable bowel syndrome, and Sjögren’s syndrome 
among the most prevalent. 
Description of Clinical Data: Multiple Chemical Sensitivity 
At the time of responding to the survey, the years of disease status 
ranged between 0 and 30, with a mean of 8.5 (SD = 7.1). 
Overall, the degree of disease status was high with a mean score 
of 235 (SD = 45.2). Table 2 summarizes the different central tendency 
measures (mean, standard deviation, minimum, and maximum 
scores) obtained for each of the scales of the QEESI, and for the years 
of disease progression. The table also contains the overall data sub-
grouped according to disease severity: moderate (n = 25) and severe 
(n = 100). Considering the high degree of impact of the disease on the 
study sample, the cutoff was established as one standard deviation 
below QEESI mean score, which corresponded to a score of 190. 
Comparisons between the two subgroups were statistically 
significant for all scales of QEESI, as well as for the total score 
obtained from the sum of the three scales. The difference between 
the two degrees of severity is not statistically significant for the years 
of disease progression (Table 2). 
Table 3 summarizes the three QEESI scales. The most affected 
systems in the severity of symptoms scale are the dermatological, 
gastrointestinal, musculoskeletal and neurological systems. The 
products that induced intolerance were insecticides, bleach, 
household cleaners, perfumes, and air fresheners. The most affected 
life-style areas were maintaining daily personal hygiene, household 
cleaning, and work or study.
Description of Clinical Data: Suffering
The mean score for suffering was 53.7 (SD = 20.6). The three 
dimensions of suffering (physical, psychological, and existential) for 
the overall study sample (sum of the 3 dimension scores) and for 
moderate vs. severe MCS subgroups are summarized in Table 4. The 
maximum possible score was 30 on the physical suffering scale, 45 
on the psychological scale, and 36 on the existential scale. Because of 
the differences in scoring of the three dimensions, we expressed the 
sum of the scores as an overall percentage so as to improve 
comparisons. In general, the physical sphere of suffering was the 
Table 1
Demographic characteristics of the study participants (N = 125)
Characteristic Category                    Mean (SD) Frequency %
Age (years) 47.6 (9.2)
Gender Female 114 91.2
Male 11 8.8
Environment Urban 105 84
Rural 20 16
Education University 49 39.2
Professional training 32 25.6
Secondary 26 20.8
Primary 18 14.4
Employment status Permanent disability 36 29.3
Unemployed 24 19.5
Temporary disability 22 17.9
Actively employed 21 17.1
Housewife 10 8.1
Retired 5 4.1
Student 4 3.2
Civil status Married 75 61
Single 25 20.3
Divorced 22 17.9
Household composition Living with partner and children 73 59.4
Living alone 24 19.5
Others 26 21.1
Comorbidities Fibromyalgia 90 71.4
Chronic fatigue 100 78.7
Others 58 47.9
Table 2
Disease severity and scores on the diagnostic questionnaires
Overall Moderate disease Severe disease t* p
Mean (SD) Range Mean (SD) Range Mean (SD) Range
YDD 8.5 (7.1) 0-30 8.2 (7.3) 0-25 8.6 (7.1) 1-30 -0.221 .826
QSEV 71.4 (17.7) 21-100 52 (17.1) 21-85 76.2 (14.3) 41-100 -7.277 < .001
QINT 82.8 (20.6) 11-100 54.1 (23.7) 11-95 89.9 (11.6) 43-100 -7.344 < .001
QLI 80.9 (17.5) 17-100 54 (15.4) 17-86 87.6 (9.8) 48-100 -10.401 < .001
QTS 235 (45.2) 117-299 160.1 (20) 117-189 253.8 (26.4) 193-299 -16.584 < .001
Note. YDD = years of disease duration, QSEV = QEESI severity, QINT = QEESI inhalatory intolerances, QLI = QEESI life impact, QTS = QEESI total score. 
*Comparison of means between moderate and severe level; 95% CI (two tailed).
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most affected in the overall study sample, as well as in the two 
severity subgroups. This was followed by the psychological sphere 
and, finally, the existential dimension. All scores were higher in the 
severe disease category than in the moderate disease subgroup.
Table 5 summarizes the responses to the different scales of 
suffering. Of note was that in the physical dimension of suffering, 
musculoskeletal and respiratory problems were those that 
produced more discomfort, whereas in the psychological 
dimension the feelings that produced more discomfort were 
worry or anxiety and lack of gaiety. In the existential area, 
thoughts of lack of inner harmony and a sense of failure in life 
were the most intense.
Table 3
Description of QEESI scales
Severity Intolerances Life impact
Item Mean (SD) Item Mean (SD) Item Mean (SD)
Muscles or joints 7.6 (2.4) Gasoline exhaust 8.0 (2.8) Diet 7.9 (2.7)
Breathing 7.1 (2.5) Tobacco 7.7 (2.8) Work/school 8.9 (2.1)
Cardiologic 6.4 (2.8) Insecticide 8.9 (2.1) Home furnish 6.2 (6.2)
Digestive 7.7 (2.6) Petrol station 8.0 (2.8) Clothing 7.0 (3.1)
Neurological 7.5 (2.5) Paint 8.7 (2.3) Travel 8.3 (2.7)
Mood 6.9 (2.9) Cleaning products 8.9 (2.0) Personal care 8.9 (2.4)
Balance 6.8 Perfumes 8.9 (2.3) Social activities 8.7 (2.3)
Headaches 7.1 (2.6) Asphalt 8.2 (6) Hobbies 8.6 (2.2)
Dermatologic 7.7 (2.6) Nail polish 8.4 (2.4) Relationships 8.0 (2.2)
Urinary 7.0 (2.8) Carpet or plastic 7.8 (2.8) House cleaning 8.9 (1.6)
Total Score 71.4 (17.7) TS 82.8 (20.6) TS 80.9 (17.5)
Table 4
Clinical characteristics
Overall Moderate Severe t* Sig.
M (SD) Range % M (SD) Range % M (SD) Range %
PhS 19.7 (5.6) 6-30 65.7 14.5 (6) 6-25 48.3 21 (4.6) 9-30 70 -5.023 .001
PS 21.6 (9.6) 3-44 48 15.6 (8.3) 4-30 34.6 23.1 (9.4) 3-44 51.3 -3.653 .001
ES 12.8 (8.7) 0-31 35.5 9.2 (7.6) 0-29 25.5 13.7 (8.8) 0-31 38.1 -2.353 .020
STS 53.7 (20.6) 14-98 48.4 39.3 (18.5) 14-78 35.4 57.3 (19.5) 15-98 51.6 -5.872 .001
Note. *Comparison of means between moderate and severe levels. C.I. 95%, two-tailed. PhS = physical suffering, PS = psychological suffering, ES = existential suffering, STS = 
suffering total score.
Table 5
Suffering scales. Proportion of people providing a response
Physical N AL QB VM Psychological N AL QB VM Existential N AL A QB VM
Muscles or joints 2 13 27 58 Afraid 26 29 35 10 I felt peaceful 28 24 28 16 4
Breathing 1 19 45 35 Confident 15 39 33 13 I had a reason for living 11 13 20 28 28
Cardiologic 15 30 36 19 Worried/Anxious 3 26 34 37 My life had been a failure 32 23 10 20 15
Digestive 7 19 34 40 Irritable 6 41 31 22 I had no peace of mind 22 23 18 22 15
Neurological 4 19 28 49 Depressed 19 40 21 20 I felt purpose in my life 19 22 16 25 18
Mood 6 27 37 30 Cheerful 17 60 16 7 I felt harmony within myself 38 26 19 12 5
Balance 10 24 34 32 Hopeless 15 32 30 23 My life lacked purpose 45 16 7 20 12
Headaches 6 27 37 30 Sad, blue 9 33 38 20 I know that despite my illness, things 
might be okay
29 25 20 15 11
Dermatologic 6 19 39 36 Burden to others 21 25 33 21 Life was not worth living 48 17 12 17 6
Urinary 12 24 38 26 Angry 11 44 27 18
Lonely 18 26 27 29
Embarrassed 50 33 11 6
Guilty 48 22 20 10
Abandoned 32 36 19 13
Rejected 31 30 29 10
Note. N = not at all, AL = a little, QB = quite a bit, S = somewhat, VM = very much.
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Associations between Study Variables
Table 6 highlights the correlations (Pearson’s r coefficients) 
between the QEESI scales and the 3 dimensions of suffering, and 
between the total scores of the QEESI variables and suffering. There 
was a high positive correlation between severity scales, impact on 
life-style, and all measures of suffering. The Intolerance scale did not 
segregate with suffering (low r coefficient).
A linear regression analysis with the three subscales of QEESI as 
predicting variables and suffering as the dependent variable (see 
Table 7) showed that the equation was statistically significant (F = 
24.720, p < .001) and explained 38.2% of the variance in the total 
score of suffering (R2 = .382) and with significance in the three 
measured variables: severity of illness (B = 0.581), chemical 
intolerances (B = -0.270) and life impact (B = 0.334). 
Discussion
The current study provides the initial approach to suffering in 
people diagnosed with MCS. In Spain, it is a poorly documented 
disease among the general population and among health-care 
professionals as well. This had prompted us to evaluate in detail the 
clinical and socio-demographic characteristics of participants, their 
suffering and the associated factors. Our findings are similar with 
respect to gender, age and comorbidity to those found by Nogué et 
al. (2007) with, in our study, a slightly higher percentage of those 
with permanent disability and years of disease evolution.
According to the QEESI scores, there were high levels of disease 
on the three scales, with mean scores significantly higher than cut-
off points recommended by Miller and Prihoda (1999). The scores in 
the Nogué et al.’s study (2007) were similar in severity and 
intolerance scales, but considerably higher, in our study, on the life 
impact scale (80.86 vs. 66.6)
The comparison of our data with those obtained by Nogué et al. 
in 2007 suggests: 1) an increase in years-of-evolution of the disease; 
2) an increase in work disability; and 3) an increase in the impact on 
daily-life activities. These results could indicate that the evolution of 
the disease is conducive to greater disability. However, our study 
showed no differences in severity in relation to years-of-evolution of 
the disease. 
We observed, in relation to suffering, that the most affected 
dimension of suffering was the physical with respect to severe and 
moderate levels of disease, followed by the psychological and, finally, 
the existential dimension. Apart from the suffering inherent in the 
physical problems, the disease causes the individual considerable 
worry or anxiety, sadness, fear, and feelings of lack of purpose in 
their lives. These symptoms are often aggravated as the disease 
progresses, or the longer the disease remains untreated. 
The high correlations between disease and different dimensions 
of suffering have, however, an exception in the case of inhalation 
intolerances scale. Here the correlations with all dimensions of 
suffering are weak, even being reversed in the case of existential 
suffering. These results could be explained by the Threat and 
Resources Model (Bayés et al., 1996), according to which the patients 
would be evaluating symptoms and the limitations they pose on 
their daily lives because they did not have enough resources to cope 
with the symptom-provoking event. However, the chemicals to 
which they are intolerant, although being the cause of discomfort, 
can be avoided in some cases and, as such, the threat is reduced. The 
disease has a variable course in which it is possible to reduce the 
symptoms if living in a toxin-free environment. However, opting for 
a toxin-free environment poses other problems such as social 
wellbeing and employment opportunities (Gibson et al., 2011) and, 
hence, a balance needs to be stuck by the individual between all 
these competing areas of a person’s lifestyle.
Apart from the analysis of intolerance scale described above, of 
considerable note was the negative correlation between intolerance 
and existential suffering. This inverse trend could be indicative of a 
greater adjustment to the illness, i.e., the more serious the 
intolerances the greater the individual’s need to avoid such 
threatening substances and a better adjustment to the disease. This 
is concordant with the findings of Nordin et al. (2010) who showed 
that the avoidance strategy is the most effective way of coping with 
the problem.
Although the correlations between severity of disease and 
dimensions of suffering are significant, these associations are less 
strong in existential suffering. One explanation could be that the 
causes of this weaker association is that in moderate degree of 
disease when physical limitations and everyday life limitations are 
few, the expectation of future limitations and breaking-off of vital 
projects could imply a loss that affects the existential sphere.
Our study has some limitations that need to be considered in 
future investigations. Firstly, given that there are no normative data 
in this population, there is considerable difficulty in comparing and 
interpreting the scores on suffering. Our study population did not 
contain individuals with the mild form of the disease. This was 
probably due to the fact that only those individuals with moderate-
to-severe disease were affected enough to contact the webpage 
and/or that the ones with mild disease had not as yet been 
diagnosed with MCS. A further limitation is that although we 
evaluated the physical, psychological, and existential aspects of the 
suffering, one real consequence of the disease is severe isolation, 
the social trauma of which we were unable to explore in the current 
study. 
Knowing the causes of an individual’s suffering is essential 
when addressing possible solutions. In this respect, our study 
provides a comprehensive quantitative assessment of suffering in 
individuals with MCS. As for other ambiguous chronic illnesses 
(Johnson & Johnson, 2006), such knowledge will help health-care 
providers to identify and diagnose the symptoms since the organic 
causes for the symptoms are not easy to identify. Further, our data 
provide a basis for specific future therapies, with the hope of 
reducing the suffering.
Table 6
Pearson correlations
1 2 3 4 5 6 7 8
1. QEESI severity -
2. QEESI intolerances .296** -
3. QEESI life  impact .547** .627** -
4. Level MCS .737** .813** .885** -
5. Physical suffering .851** .186* .488** .606** -
6. Existential suffering .345** -.024 .226* .211* .447** -
7. Psychological suffering .473** .060 .358** .351** .565** .813** -
8. Suffering total score .575** .052 .387** .398** .701** .903** .944** -
*Correlation is significant at .05 level (two-tailed)
**Correlation is significant at .01 level (two-tailed)
Table 7
Regression analysis of factors associated with suffering in MCS (N = 125)
Independent variables B t p
R2 = .382
Illness severity 0.581 5.786 .000
Chemical intolerances -0.270 -2.928 .004
Life impact 0.334 2.696 .008
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Conclusions
MCS is a disease that causes physical, psychological, and 
existential suffering. The severity of symptoms generates the most 
suffering, followed by QoL constraints, while the number and 
severity of inhalation intolerances decrease overall suffering. 
Musculoskeletal and respiratory problems cause the most physical 
suffering. Psychological suffering is marked by worry or anxiety and 
joylessness. Existential suffering reveals thoughts of failure and lack 
of inner harmony.
Relevance to Clinical Practice
This study provides a detailed description of MCS and the 
consequences that the disease has on the individual. This knowledge 
can provide the bases for future therapies. Given the current lack of 
knowledge of the disease on the part of health-care professionals, 
and the consequent lack of attention of these patients, the findings 
may help sensitize health-care workers to this problem, which can 
only increase with progressively increasing industrial and domestic 
pollutants. 
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Appendices
I. QEESI
SYMPTOMS 
1. Problems with your muscles or joints, such as pain, aching, cramping, stiffness or 
weakness.
0 1 2 3 4 5 6 7 8 9 10
2. Problems with burning or irritation of your eyes, or problems with your airway or 
breathing, such as feeling short of breath, coughing, or having a lot of mucus, post-nasal 
drainage, or respiratory infections.
0 1 2 3 4 5 6 7 8 9 10
3. Problems with your heart or chest, such as a fact or irregular heart rate, skipped 
beats, your heart pounding, or chest discomfort.
0 1 2 3 4 5 6 7 8 9 10
4. Problems with your stomach or digestive tract, such abdominal pain or cramping, 
abdominal swelling or bloating, nausea, diarrhea, or constipation.
0 1 2 3 4 5 6 7 8 9 10
5. Problems with your ability to think, such as difficulty concentrating or remembering 
things, feeling spacey, or having trouble making decisions
0 1 2 3 4 5 6 7 8 9 10
6. Problems with your mood, such as feeling tense or nervous, irritable, depressed, 
having spells or crying or rage, or loss of motivation to do things that used to interested 
you.
0 1 2 3 4 5 6 7 8 9 10
7. Problems with balance or coordination, with numbness o tingling in your extremities, 
or with focusing your eyes.
0 1 2 3 4 5 6 7 8 9 10
8. Problems with your head, such as headaches or a feeling of pressure or fullness in 
your face or head.
0 1 2 3 4 5 6 7 8 9 10
9. Problems with your skin, such as a rash, hives or dry skin. 0 1 2 3 4 5 6 7 8 9 10
10. Problems with your urinary tract or genitals, such as pelvic pain or frequent or 
urgent urination( for women: or discomfort or other problems with your menstrual 
period)
0 1 2 3 4 5 6 7 8 9 10
INHALATORY CHEMICAL EXPOSURES
1. Diesel or gasoline exhaust 0 1 2 3 4 5 6 7 8 9 10
2. Tobacco smoke 0 1 2 3 4 5 6 7 8 9 10
3. Insecticide 0 1 2 3 4 5 6 7 8 9 10
4. Gasoline 0 1 2 3 4 5 6 7 8 9 10
5. Paint or paint thinner 0 1 2 3 4 5 6 7 8 9 10
6. Cleaning products 0 1 2 3 4 5 6 7 8 9 10
7. Fragrances 0 1 2 3 4 5 6 7 8 9 10
8. Tar or asphalt 0 1 2 3 4 5 6 7 8 9 10
9. Nail polish or hairspray 0 1 2 3 4 5 6 7 8 9 10
10. New furnishings 0 1 2 3 4 5 6 7 8 9 10
IMPACT OF SENSITIVITIES
1. Diet 0 1 2 3 4 5 6 7 8 9 10
2. Ability to work or attend school 0 1 2 3 4 5 6 7 8 9 10
3. Choice of home furnishings 0 1 2 3 4 5 6 7 8 9 10
4. Choice of clothing 0 1 2 3 4 5 6 7 8 9 10
5. Ability to drive or travel 0 1 2 3 4 5 6 7 8 9 10
6. Choice of personal care products 0 1 2 3 4 5 6 7 8 9 10
7. Ability to be around others and enjoy social activities , for example going to meetings, 
church, restaurants, etc.
0 1 2 3 4 5 6 7 8 9 10
8. Choice of hobbies or recreation 0 1 2 3 4 5 6 7 8 9 10
9. Relationships with spouse and family 0 1 2 3 4 5 6 7 8 9 10
10. Ability to perform household chores, or iron. 0 1 2 3 4 5 6 7 8 9 10
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II. SUFFERING SCALES
PHYSICAL SUFFERING: How much did the following symptom bother or distress 
you during the past seven days?
Not at 
all
A little Quite a 
bit
Very 
Much
1. Musculoskeletal 0 1 2 3
2. Eyes, Airway 0 1 2 3
3. Heart/chest-related 0 1 2 3
4. Gastrointestinal 0 1 2 3
5. Cognitive 0 1 2 3
6. Affective 0 1 2 3
7. Neuromuscular 0 1 2 3
8. Headache 0 1 2 3
9. Skin 0 1 2 3
10. Genitourinary 0 1 2 3
PSYCHOLOGICAL SUFFERING: Please indicate how often you experienced the 
emotions listed below during the past 7 days.
Not at 
all
A little Quite a 
bit
Very 
Often
1. Afraid 0 1 2 3
2. *Confident. 0 1 2 3
3. Worried or anxious. 0 1 2 3
4. Irritable. 0 1 2 3
5. Depressed. 0 1 2 3
6. *Cheerful. 0 1 2 3
7. Hopeless. 0 1 2 3
8. Sad, blue 0 1 2 3
9. Burden to others 0 1 2 3
10. Angry 0 1 2 3
11. Lonely 0 1 2 3
12. Embarrassed about yourself 0 1 2 3
13. Guilty 0 1 2 3
14. Abandoned 0 1 2 3
15. Rejected 0 1 2 3
EXISTENTIAL SUFFERING: Please indicate how true each statement has been for 
you during the past 7 days.
Not at 
all
A little Somewhat Quite 
a bit
Very 
much
*I felt peaceful. 0 1 2 3 4
*I had a reason for living 0 1 2 3 4
My life had been a failure. 0 1 2 3 4
I had trouble feeling peace of 
mind
0 1 2 3 4
*I felt a sense of purpose in 
my life
0 1 2 3 4
*I felt a sense of harmony 
within myself
0 1 2 3 4
My life lacked meaning and 
purpose.
0 1 2 3 4
*I know that whatever 
happens with my illness, 
things will be okay.
0 1 2 3 4
Life was not worth living 
anymore
0 1 2 3 4
